Medicenna Therapeutics Corp
(MDNAF)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 03/31
(Values in U.S. thousands)
| 03-2025 | 03-2024 | 03-2023 | 03-2022 | 03-2021 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 17,850 | 12,589 | 25,415 | 16,383 | 23,021 |
| Marketable Securities | N/A | N/A | N/A | N/A | 7,587 |
| Receivables | 1,937 | 863 | 647 | 1,044 | 311 |
| Other current assets | 459 | 690 | 1,463 | 1,235 | 1,026 |
| TOTAL | $20,247 | $14,142 | $27,525 | $18,661 | $31,945 |
| Non-Current Assets | |||||
| PPE Net | 13 | N/A | N/A | N/A | N/A |
| Intangibles | 37 | 42 | 46 | 52 | 54 |
| Other Non-Current Assets | 101 | 0 | 0 | 0 | 24 |
| TOTAL | $152 | $42 | $46 | $52 | $78 |
| Total Assets | $20,398 | $14,184 | $27,571 | $18,713 | $32,023 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 3,152 | 2,122 | 2,875 | 2,091 | 3,087 |
| TOTAL | $3,187 | $2,122 | $2,875 | $2,091 | $3,113 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 3,487 | 8,214 | 2,391 | 0 | 0 |
| TOTAL | $3,487 | $8,214 | $2,391 | $N/A | $N/A |
| Total Liabilities | $6,675 | $10,336 | $5,265 | $2,091 | $3,113 |
| Shareholders' Equity | |||||
| Common Shares | 83,583 | 74,815 | 76,349 | 66,753 | 60,319 |
| Retained earnings | -84,988 | -78,909 | -61,262 | -56,590 | -36,649 |
| Other shareholders' equity | 7,068 | 14 | 43 | 137 | 177 |
| TOTAL | $13,724 | $3,848 | $22,306 | $16,622 | $28,910 |
| Total Liabilities And Equity | $20,398 | $14,184 | $27,571 | $18,713 | $32,023 |